Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN), a commercial-stage psychedelic pharmaceutical manufacturer, announced its support for final recommendations from Australia's Therapeutic Goods Administration (TGA) regarding the Authorized Prescriber scheme for psilocybin and MDMA. The updated framework broadens eligible therapy teams, expands treatment settings beyond hospital environments, and supports scaling of psychedelic-assisted therapy across Australia, where authorized psychiatrists can prescribe Optimi's GMP-compliant MDMA for post-traumatic stress disorder (PTSD) and psilocybin for treatment-resistant depression.
The company said the revised framework could accelerate adoption of psychedelic-assisted therapy by increasing workforce capacity, particularly in rural and regional areas, while expanding reimbursement opportunities across both public and private payers. Optimi also noted that no serious adverse events have been reported under Australia's regulated commercial psychedelic treatment program since December 2025, supporting continued expansion of what the company describes as the world's most advanced commercial market for prescribed psilocybin and MDMA therapies.
Australia's move to refine its regulatory environment for psychedelic therapies signals a growing acceptance of these treatments in mainstream mental health care. For business leaders and investors, the development underscores the potential for scalable, regulated markets in psychedelic medicine. Optimi, as a GMP-certified manufacturer, is well-positioned to supply the increasing demand, especially as the updated framework removes previous barriers such as mandatory hospital-based administration. This could lead to cost reductions and improved patient access, potentially driving higher adoption rates and creating a more predictable revenue stream for companies like Optimi.
The expansion of eligible therapy teams and treatment settings is particularly significant for rural and regional areas, which often face shortages of mental health professionals. By enabling more psychiatrists to prescribe and supervise treatments, the TGA's changes could help bridge the gap in care. Additionally, the potential for reimbursement from public and private payers may make these therapies more affordable and accessible, further stimulating market growth.
Optimi's emphasis on safety data—with no serious adverse events reported since December 2025—provides a strong foundation for regulatory confidence and public acceptance. This track record could encourage other jurisdictions to consider similar frameworks, potentially positioning Australia as a model for global psychedelic therapy regulation. For the pharmaceutical industry, the development highlights the importance of robust manufacturing standards and clinical evidence in gaining regulatory approval and market traction.
The full press release is available at https://nnw.fm/yYW7j. More information about Optimi Health Corp. can be found at https://www.optimi.net/.
